Last reviewed · How we verify
rifapentine + isoniazid
Rifapentine inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis, while isoniazid inhibits the synthesis of mycolic acid and the metabolism of fatty acids.
Rifapentine inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis, while isoniazid inhibits the synthesis of mycolic acid and the metabolism of fatty acids. Used for Treatment of tuberculosis, Prevention of tuberculosis in HIV-infected individuals.
At a glance
| Generic name | rifapentine + isoniazid |
|---|---|
| Also known as | Priftin (rifapentine) |
| Sponsor | The Aurum Institute NPC |
| Drug class | Antitubercular |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Rifapentine and isoniazid work synergistically to inhibit the growth of Mycobacterium tuberculosis by disrupting its cell wall synthesis and fatty acid metabolism. This leads to the death of the bacteria and ultimately, the resolution of tuberculosis infection.
Approved indications
- Treatment of tuberculosis
- Prevention of tuberculosis in HIV-infected individuals
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Fatigue
Key clinical trials
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2, PHASE3)
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women (PHASE1)
- Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings (NA)
- A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV (PHASE1, PHASE2)
- One-month Latent Tuberculosis Treatment for Renal Transplant Candidates (PHASE4)
- ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rifapentine + isoniazid CI brief — competitive landscape report
- rifapentine + isoniazid updates RSS · CI watch RSS
- The Aurum Institute NPC portfolio CI